Last reviewed · How we verify
Concurrent Lenvatinib
Lenvatinib is a multi-targeted tyrosine kinase inhibitor that blocks FGFR, VEGFR, RET, and KIT signaling to inhibit tumor angiogenesis and growth.
Lenvatinib is a multi-targeted tyrosine kinase inhibitor that blocks FGFR, VEGFR, RET, and KIT signaling to inhibit tumor angiogenesis and growth. Used for Advanced hepatocellular carcinoma (in combination therapy), Differentiated thyroid cancer, Renal cell carcinoma (in combination therapy).
At a glance
| Generic name | Concurrent Lenvatinib |
|---|---|
| Also known as | Concurrent targeted therapy |
| Sponsor | Sun Yat-sen University |
| Drug class | Multi-targeted tyrosine kinase inhibitor |
| Target | FGFR1-4, VEGFR1-3, RET, KIT |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Lenvatinib inhibits multiple receptor tyrosine kinases involved in tumor angiogenesis and proliferation, including fibroblast growth factor receptors (FGFR1-4), vascular endothelial growth factor receptors (VEGFR1-3), RET proto-oncogene, and KIT. By blocking these pathways, it reduces tumor blood vessel formation and directly suppresses cancer cell growth. The 'concurrent' designation suggests this is being studied in combination with another therapeutic agent.
Approved indications
- Advanced hepatocellular carcinoma (in combination therapy)
- Differentiated thyroid cancer
- Renal cell carcinoma (in combination therapy)
Common side effects
- Hypertension
- Diarrhea
- Fatigue
- Decreased appetite
- Nausea
- Proteinuria
- Weight loss
- Vomiting
Key clinical trials
- Safety and Efficacy of LVD + C-TACE + Tis/Len for Unresectable Right-Liver HCC (NA)
- The Safety and Efficacy of Ondansetron in Reducing Immune Checkpoint Inhibitor-Related Toxicities (PHASE2)
- Phase II Study of Concurrent Lenvatinib and Radiotherapy for Advanced HCC (PHASE2)
- Lenvatinib and Pembrolizumab Simultaneous Combination Study (PHASE2)
- Concurrently vs Sequentially Combined HAIC With Targeted and Immunotherapy in Potentially Resectable HCC (PHASE3)
- Phase II Study of Moderate-dose Hypofractionated RT Combined With Pembrolizumab for HCC With Diffuse Tumor Thrombosis (PHASE2)
- HAIC Combined With Durvalumab and Tremelimumab and Lenvatinib in uHCC (PHASE2)
- Phase II Study of Moderate-dose Hypofractionated RT Combined With Tislelizumab for HCC With Diffuse Tumor Thrombosis (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |